Missoula, Montana 59812


- Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users - Assess creatine's effect on methamphetamine use - Assess the safety of creatine in male methamphetamine users with depression


Inclusion Criteria: - Current primary diagnosis of methamphetamine dependence or abuse, with methamphetamine preferred drug of abuse - Current diagnosis of major depressive disorder (primary or substance-induced) - Current diagnosis of an anxiety disorder (primary or substance-induced) - Current Hamilton Depression Rating scale score > or = to 16 - Current Hamilton Anxiety Scale score > = to 18 - If taking a psychotropic medication for depressed or anxious mood, regimen must be stable for > = to 4 weeks prior to creatine treatment initiation Exclusion Criteria: - Persons unable to provide adequate informed consent - Persons who are at clinically significant suicidal or homicidal risk - Primary substance-related diagnosis other than methamphetamine dependence or abuse - Positive pregnancy test (females only) - History of renal disease - Clinically significant medical or neurological illness identified by history, physical exam and laboratory testing - History of hypersensitivity reaction to creatine



Primary Contact:

Principal Investigator
Tracy Hellem, PhD
Montana State University

Tracy Hellem, PhD
Phone: 406 243 2110
Email: tracy.hellem1@montana.edu

Backup Contact:


Location Contact:

Missoula, Montana 59812
United States

Tracy Hellem, PhD
Phone: 406-243-2110
Email: tracy.Hellem1@montana.edu

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.